Ritlecitinib safe treatment option for alopecia areata in adults and adolescents: Lancet
USA: A recent study published in The Lancet has projected ritlecitinib to be an appropriate treatment option for alopecia areata in individuals who are candidates for systemic therapy. The study found Ritlecitinib to be well tolerated and effective in patients aged 12 and above with alopecia areata. Ritlecitinib is an oral, selective dual JAK3/TEC family […] More